Pattern of well-timed bets raises questions beyond Iran episode
Prediction markets have seen very profitable bets at key unflagged moments of the Trump presidency moments
AI bubble fears cool but major IPO tests lie ahead
Classic scenario typically sees a rush of companies selling to ravenous public; the AI boom has been more marked by buy-backs
Avoiding ETF taxes may leave Irish investors missing out
New research suggests true diversification may require investment in as many as 750 companies to closely match the overall market
Despite Iran war, stock markets don’t seem especially spooked
Investors are not ignoring the war, but they are assuming it won’t last long enough to really matter
Starbucks’ Howard Schultz joins billionaire migration to Florida’s sunny tax haven
Howard Schultz joins Jeff Bezons and Sergey Brin among others switching to Florida
Retrofitting will heat your house but freeze your finances
Would cash spent beefing up your home’s Ber rating be better deployed investing in the market?
From bone spurs to ‘God’s work’: no contrition from former Goldman Sachs boss
In his new memoir, Streetwise, Lloyd Blankfein can’t resist a dig at a certain US president
AIB chief Colin Hunt’s €2.7m pay reflects return to international norms
A more than fourfold increase in one’s pay packet is attention-grabbing in any context, and especially so in Ireland
Market seatbelts on: Iran war jitters meet the buy-the-cannons rule
S&P 500 selling has been relatively contained, prompting the boss of America’s biggest bank, JPMorgan to warn of a ‘lot of complacency’
Wall Street’s latest AI jitters reveal a nervous market
Software stocks, already bloodied, were given another thump by Citrini Research’s ‘thought experiment’ blog post positing an AI apocalypse
Should Diageo sell everything else and change its name to Guinness plc?
It’s the fastest-growing beer brand in North America
Canada or Sweden? Simon Harris considers Ireland’s savings future
Swedish scheme has no cap on contributions and may be considered politically safer
Moderna’s vaccine ambitions run into a wall of ‘anti-science’ scepticism
Regulatory inconsistency and the views of US health secretary hampering medical innovation
After tariff study, Trump loyalist wants Fed authors ‘disciplined’
Economics of New York Fed’s study uncontroversial, but the politics is another matter